Last reviewed · How we verify
Prevention of Radiation Therapy-Induced Mucositis
Approved treatments
- Kepivance · Biovitrum Ab
Kepivance works by binding to fibroblast growth factor receptor 2, stimulating the growth and proliferation of mucosal cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of Radiation Therapy-Induced Mucositis patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of Radiation Therapy-Induced Mucositis treatment landscape brief
- Prevention of Radiation Therapy-Induced Mucositis treatment updates RSS
Frequently asked questions about Prevention of Radiation Therapy-Induced Mucositis
What drugs treat Prevention of Radiation Therapy-Induced Mucositis?
Tracked treatments include Kepivance.
What is the treatment for Prevention of Radiation Therapy-Induced Mucositis?
Standard treatment for Prevention of Radiation Therapy-Induced Mucositis includes Kepivance. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of Radiation Therapy-Induced Mucositis patent cliff · Prevention of Radiation Therapy-Induced Mucositis CI report
- Treatment: Kepivance · Biovitrum Ab
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing